Janssen, Bristol-Myers Squibb collaborate to develop blood clot medications

Listen to this article

Janssen Pharmaceutical Cos., part of New Brunswick-based Johnson & Johnson, has formed a partnership with Bristol-Myers Squibb to develop and commercialize potentially breakthrough oral anticoagulant medications to help prevent blood clots, including the drug BMS-986177.Janssen Pharmaceutical Cos., part of New Brunswick-based Johnson & Johnson, has formed a partnership with Bristol-Myers Squibb to develop and commercialize potentially breakthrough oral anticoagulant medications to help prevent blood clots, including the drug BMS-986177.

Under the agreement Janssen and Bristol-Myers Squibb will jointly conduct Phase II clinical trials for BMS-986177 and establish a broad development program for it across multiple therapeutic indications.

The two companies will also share development costs and commercial profits and losses.

“With the addition of a Factor XIa inhibitor program to our pipeline, Janssen continues to live up to our long-standing commitment of working tirelessly to bring truly transformational therapies to patients worldwide,” said Janssen’s Gloal Heald Dr. Mathai Mammen. “With this new collaboration we have the potential to improve the standard of care for patients with cardiovascular conditions characterized by pathologic thrombosis.”